Lionel Seltz was appointed as Chief Financial Officer of CROSSJECT on March 25, 20261
CROSSJECT is a specialty pharmaceuticals company developing emergency medicines using its proprietary ZENEO® needle-free auto-injector platform1
Seltz brings approximately 30 years of international leadership experience in finance, strategy, and operations4
Prior to joining CROSSJECT, Seltz served as CFO North Europe at Antech Diagnostics, overseeing finance across multiple countries1
He previously held CFO and executive leadership roles in listed and high-growth healthcare and technology companies1
Seltz's responsibilities at CROSSJECT will focus on financial strategy, financing optimization, operational performance, industrial scaling, and international development1
The appointment comes at a key stage as CROSSJECT advances toward registration and commercialization of ZEPIZURE® for emergency treatment of epileptic seizures1
Sources:
1. https://www.biospace.com/press-releases/crossject-appoints-lionel-seltz-as-chief-financial-officer
4. https://ml-eu.globenewswire.com/Resource/Download/ea2c25a8-4e2c-4b4c-953f-c5d0f5fc9464